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Prevalence, risk factors and molecular
epidemiology of highly resistant gram
negative rods in hospitalized patients in
the Dutch region Kennemerland
Dennis Souverein1*, Sjoerd M. Euser1, Bjorn L. Herpers1, Bram Diederen1, Patricia Houtman2, Marina van Seventer2,
Ingeborg van Ess3, Jan Kluytmans4, John W. A. Rossen5 and Jeroen W. Den Boer1
Abstract
Background: This paper describes (1) the Highly Resistant Gram Negative Rod (HR-GNR) prevalence rate, (2) their
genotypes, acquired resistance genes and (3) associated risk factors of HR-GNR colonization among the hospitalized
population in the Dutch region Kennemerland.
Methods: Between 1 October 2013 and 31 March 2014, cross-sectional prevalence measurements were performed
in three regional hospitals as part of each hospitals infection control program. Rectal swabs were analyzed at the
Regional Public Health Laboratory Kennemerland by direct culturing. Genotypes and acquired resistance genes of
positive isolates were determined using Whole Genome Sequencing with the MiSeq instrument (Illumina). Association
between several independent variables and HR-GNR positivity was examined using logistic regression models.
Results: Out of 427 patients, 24 HR-GNR positive isolates were recovered from 22 patients, resulting in a regional
HR-GNR colonization prevalence (95 % CI) of 5.2 % (3.6–7.9). Of these 22 positive patients, 15 were Extended
Spectrum Beta-Lactamase (ESBL) positive (3.5 % (2.1–5.7)), 7 patients were positive for a Fluoroquinolones and
Aminoglycosides (Q&A) resistant Enterobacteriaceae (1.6 % (0.8–3.3)) and from one patient (0.2 % (0–1.3)) a
Stenotrophomonas maltophilia resistant towards co-trimoxazole was isolated. No carbapenemase producing
Enterobacteriaceae (CPE), multi-resistant Acinetobacter species or multi-resistant Pseudomonas aeruginosa were
isolated. The ESBL genes found were blaCTX-M-1 (n = 4, 25.0 %), blaCTX-M-15 (n = 3, 18.8 %), blaCTX-M-27 (n = 2, 12.5 %),
blaCTX-M-14b (n = 2, 12.5 %), blaCTX-M-9 (n = 2, 12.5 %), blaCTX-M-14 (n = 1, 6.3 %), blaCTX-M-3 (n = 1, 6.3 %), blaSHV-11 (n = 1,
6.3 %) and blaSHV-12 (n = 1, 6.3 %). Being known HR-GNR positive in the past was the only significant associated risk
factor for HR-GNR positivity, odds ratio (95 % CI): 7.32 (1.82–29.35), p-value = 0.005.
Conclusions: Similar ESBL prevalence rates and genotypes (3.5 %) were found in comparison to other Dutch
studies. When previously HR-GNR positive patients are readmitted, they should be screened for HR-GNR colonization
since colonization with GR-GNRs could be prolonged. We recommend for future studies to include all defined
HR-GNRs in addition to ESBLs in prevalence studies, in order to obtain a more comprehensive overview of
colonization with HR-GNRs.
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Background
Worldwide there is an alarming increase in the
prevalence of Highly Resistant Gram Negative Rods
(HR-GNRs) among clinical isolates [1–3]. The emer-
gence and spread of HR-GNRs is a public health
threat since infections caused by HR-GNRs are asso-
ciated with an increased risk of morbidity, mortality,
and healthcare costs (estimated mean additional costs
per case between € 5449.- and € 27,245.-) compared
to susceptible micro-organisms [4, 5]. In the Netherlands,
the group of HR-GNRs is defined as (1) Enterobacteria-
ceae that are Extended Spectrum Beta-Lactamase (ESBL)
and/or carbapenemase positive (CPE) and/or resistant to-
wards Fluoroquinolones and Aminoglycosides (Q&A),
(2) Acinetobacter species that are CPE and/or resistant
to Q&A, (3) Stenotrophomonas maltophilia resistant
towards co-trimoxazole and (4) multi-resistant Pseudo-
monas aeruginosa (Table 1) [6].
Several Dutch studies reported ESBL (colonization)
prevalence rates in different human populations and
regions ranging from 4.7 to 10.1 % [7–12]. In addition,
molecular analyses of ESBL positive isolates found in an-
imals (veal calves, broilers and companion animals) and
humans showed several associations that suggest trans-
mission [10–14]. However, exact transmission routes
and risk factors are largely unknown since epidemio-
logical links are frequently missing, which limits the in-
terpretation of molecular typing results. Previous studies
on livestock-associated methicillin-resistant Staphylococ-
cus aureus (LA-MRSA) have shown that differences in
prevalence rates exist between different regions of the
Netherlands, stressing the importance of regional preva-
lence studies which may also apply to the HR-GNR (and
ESBL) epidemiology [15].
To our knowledge, the above mentioned prevalence
studies are the only (recent) studies carried out in the
Netherlands that determined the prevalence of ESBL-
producing Enterobacteriaceae among different human
populations. No studies were found that examined the
prevalence and genotypes of all defined HR-GNRs among
hospitalized patients (Table 1). Furthermore, the Regional
Public Health Laboratory Kennemerland (RPHLK) is a
microbiological diagnostic and expertise laboratory that
performs infectious disease diagnostics for primary,
secondary and tertiary care facilities in the Dutch re-
gion Kennemerland allowing the possibility to per-
form standardized prevalence measurements from a
regional point of view.
In this cross-sectional prevalence measurement, we
aimed to investigate (1) the HR-GNR prevalence rate,
(2) their genotypes and acquired resistance genes, and
(3) associated risk factors of HR-GNR colonization




According to the Dutch regulation for research with
human subjects, neither medical or ethical approval was
required to conduct the study since the data were
collected as part of each hospitals standard infection
control program. Additionally, we received approval to
conduct the study from the institutional review board of
the Spaarne Gasthuis. The data were anonymized and
analyzed under code.
Study design, setting, participants, data collection and
variables
Between 1 October 2013 and 31 March 2014, cross-
sectional (point)prevalence measurements were per-
formed in the three regional hospitals in the Dutch
region Kennemerland as part of each hospitals infection
control program. Rectal swabs were obtained from hospi-
talized patients (independent of the hospitalization time)
at all participating wards (internal medicine, cardiology,
neurology, surgery, urology, pulmonology, intensive care
unit, pediatrics, geriatrics, orthopedics and gynecology).
Outpatients as well as patients on day care were excluded.
Additionally, the following data were obtained from
the hospital and laboratory information system in order
to identify possible risk factors: (1) basic patient charac-
teristics (gender and age), (2) antibiotic usage (during
current admission and up-to six months before admis-
sion), (3) admission information (during current admis-
sion and up to 1 year before admission) and (4) historic
HR-GNR isolates (since January 2008).
Laboratory detection HR-GNRs
Rectal swabs (Copan eSwab including 1 mL of modi-
fied liquid amies) were analyzed for the presence of
HR-GNRs at the RPHLK by direct culturing on both
an ESBL screening agar (ChromID ESBL-ID, bioMer-
ieux, enriched with a mixture of antibiotics, including
cefpodoxime) and a CLED GM20 agar (with 20 mg/L
gentamicin, Oxoid). Gram-negative rods growing on
Table 1 Dutch HR-GNR definition
Organism ESBL CAR QUI AMG CFT PIP COT
Enterobacteriaceae A A B B - - -
Acinetobacter species - A B B - - -
Stenotrophomonas maltophilia - - - - - - A
Pseudomonas aeruginosa - C C C C C -
A: This type of resistance mechanism or resistance against this antimicrobial
agent indicates a HR-GNR
B: Resistance against minimal two antimicrobial agents indicates a HR-GNR
C: Resistance against minimal three antimicrobial agents indicates a HR-GNR
ESBL extended spectrum beta lactamase, CAR carbapenems, QUI
fluoroquinolones, AMG aminoglycosides
CFT ceftazidime, PIP piperacillin, COT co-trimoxazole
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these two agars were identified using MALDI-TOF
(Bruker Daltonics, Germany). Antibiotic susceptibility
testing was performed using the automated system
VITEK2 (bioMérieux, France). All isolates suspected
for the production of ESBL were confirmed using the
combination disk method (ceftazidime and cefotaxime
or cefepime with and without clavulanic acid) [16].
Strains suspected for carbapenemase production were
confirmed using the modified Hodge test [16]. All
positive isolates were stored at −80 °C.
Molecular characterization of HR-GNR positive isolates by
whole genome sequencing
DNA was extracted using the UltraClean microbial
DNA isolation kit (Mo Bio Laboratories, Carlsbad, CA,
USA) according to the manufacturer’s protocol. A DNA
library was prepared using the Nextera XT kit (Illumina,
San Diego, CA, USA) according to the manufacturer’s
instructions. Subsequently, Whole Genome Sequencing
(WGS) was performed using the MiSeq instrument
(Illumina) for generating paired-end 250-bp reads,
aiming at a coverage of at least 60-fold. De novo as-
sembly was performed as described previously using
CLC Genomics Workbench v7.0.3 (CLC bio A/S, Aarhus,
Denmark) after quality trimming (Qs ≥ 28) with optimal
word sizes based on the maximum N50 value [17, 18].
The sequence type (ST) was identified by uploading the
assembled genomes to the multilocus sequence type
(MLST) server (version 1.7) and the acquired resistance
genes were determined with the CGE Resfinder 1.2 tool
[19, 20]. STs previously undescribed were submitted to
Stenotrophomonas maltophilia MLST database (http://
pubmlst.org/smaltophilia/), to the Enterobacter cloacae
MLST database (http://pubmlst.org/ecloacae/) or to the
Enterobase database (http://enterobase.warwick.ac.uk/).
Infection prevention policy in the participating hospitals
The infection prevention policy in the three regional
hospitals is based on the Dutch Working party of Infec-
tion prevention (WIP), which is considered highly ef-
fective and widely accepted by all Dutch hospitals in
order to prevent nosocomial spread of Multi Drug Re-
sistant Micro-Organisms (MDROs) [6]. The hospitals
infection prevention policy includes the training of hos-
pital staff (such as not wearing hand jewelry and the
daily use of clean hospital uniforms). Patient rooms are
daily cleaned and disinfected when indicated. As part of
the policy, patients with an increased risk of HR-GNR
acquisition, such as admission in a hospital abroad are
screened before admission and nursed in contact isola-
tion, consisting of: (1) nursing in a single room (2) the
use of protective clothing, including gloves and gown
and/or mask (when indicated), (3) compliance to hand
hygiene protocols and (4) disinfection of medical
devices and equipment after use. In addition, an alert
pop-up is entered in the hospital information system as
warning when HR-GNR positive patients are readmit-
ted to the hospital. In case of an unexpected HR-GNR
positive patient, all contacts (patients that were still
hospitalized and shared the same room with the index
patient for at least 24 h during the current hospital
stay) were screened for HR-GNR colonization and iso-
lated (when positive) as described.
Outcomes and data analysis
The primary outcome was the rectal HR-GNR preva-
lence rate at patient level. These prevalence rates were
calculated by dividing the number of HR-GNR positive
patients (and per HR-GNR subgroup) by the total num-
ber of sampled patients. Confidence intervals (95 %) of
the prevalence rates were calculated using the Wilson
score [21]. Proportions (such as prevalence rates and
type of micro-organism) were compared between hospi-
tals using the Pearson chi-square test or Fisher’s exact
test (when appropriate).
The association between several independent vari-
ables (sex, age, historic antibiotic use, antibiotic use
during admission, historic admission (up to 1 year),
known HR-GNR positive in the past (since January
2008) and time from start admission to sampling) and
the dependent variable HR-GNR positivity (yes/no)
was examined using logistic regression models. These
associations were presented as odds ratio’s, including
95 % confidence intervals and p-values. The inde-
pendent continuous variables were first checked for
linearity and when not linear associated reported as
quartiles. Univariate significant associations were fur-
ther analyzed using a multivariate logistic regression
model. All analyses were performed using PASW
SPSS Statistics version 18.0. Results were interpreted
as statistically significant when the p-value was < 0.05.
Results
Study population
In total, out of 566 eligible patients, 427 patients (75.4 %)
were sampled during this present regional prevalence
measurement. The mean age (SD) of this study popula-
tion was 65.1 (21.1) years and 217 patients (50.8 %)
were male. The median time (range) between admission
and sampling was 3 (0–48) days. From all sampled
patients, twelve (2.8 %) patients were known to be HR-
GNR positive in the past (since January 2008) of whom
three (25.0 %) patient(s) were positive and nine (75.0 %)
were negative in the present prevalence measurement.
The median time (range) between the first HR-GNR
positive isolate and the current prevalence measure-
ment for the three positive and nine negative patients was
414 (69–1991) and 648 (28–2273) days, respectively. A
Souverein et al. Antimicrobial Resistance and Infection Control  (2016) 5:8 Page 3 of 10
total of 167 (39.3 %) patients used antibiotics during
the present hospital stay and 99 (23.3 %) patients
used antibiotics up to 6 months before the present
hospital stay. A total of 204 patients (48.0 %) were
admitted (up to 1 year) before the present hospital
stay. Stratified study population characteristics for the
separate hospitals are shown in Table 2. From two
patients, no demographic and historic data were avail-
able and these were excluded from further analyses.
Prevalence of HR-GNRs and micro-organisms in hospitalized
patients
A total of 22 patients were culture positive for one or
more types of HR-GNRs, resulting in a regional HR-
GNR colonization prevalence (95 % CI) of 5.2 %
(3.6–7.9). Of these 22 positive patients, 15 were ESBL
positive (3.5 % (2.1–5.7)), 7 patients were positive
with an isolate resistant towards Q&A (1.6 % (0.8–3.3))
and from one patient (0.2 % (0–1.3)) a Stenotrophomonas
maltophilia resistant towards co-trimoxazole was isolated.
No CPE, multi-resistant Acinetobacter species or multi-
resistant Pseudomonas aeruginosa were isolated. From
three patients (0.7 %), more than one distinctive HR-GNR
phenotype was isolated of whom one patient (0.2 %) was
positive for more than one type of HR-GNR (both an
ESBL positive isolate and isolate resistant towards Q&A).
Stratified prevalence rates for each hospital and type of
HR-GNR are shown in Table 3. No statistically significant
differences in prevalence rates were found between hospi-
tals (p = 0.180). When patients were divided in two groups
based on hospitalization time, a HR-GNR prevalence
(95 % CI) of 5.3 % (2.6–10.5) and 4.7 % (2.9–7.9) was
found respectively for patients that were 0–1 day hospital-
ized (7 out of 133 patients) and longer than one day hospi-
talized (14 out of 292 patients) (p = 0.836).
Most of the isolated HR-GNR micro-organisms were
Escherichia coli (73.1 %) followed by Enterobacter cloacae
(11.5 %), Klebsiella pneumoniae (11.5 %) and Stenotropho-
monas maltophilia (3.8 %). There was no significant dif-
ference in the total distribution of all micro-organisms
between the three hospitals (p = 0.421).
Molecular characterization of ESBL positive isolates
Twenty-four HR-GNR positive isolates belonging to 22
HR-GNR positive patients were genotyped using WGS.
All 16 phenotypically ESBL positive isolates sampled
from 15 patients harbored ESBL genes of which one iso-
late (Klebsiella pneumonia, ST48) contained two ESBL
genes (blaCTX-M-15 and blaSHV-11). ESBL genes found
were blaCTX-M-1 (n = 4, 25.0 %), blaCTX-M-15 (n = 3,
18.8 %), blaCTX-M-27 (n = 2, 12.5 %), blaCTX-M-14b (n = 2,
12.5 %), blaCTX-M-9 (n = 2, 12.5 %), blaCTX-M-14 (n = 1,
6.3 %), blaCTX-M-3 (n = 1, 6.3 %), blaSHV-11 (n = 1, 6.3 %)
and blaSHV-12 (n = 1, 6.3 %) (Table 4).
Eleven of the 16 ESBL positive isolates were deter-
mined as Escherichia coli (68.8 %). ST131 was found
twice (12.5 %) and both isolates harbored the blaCTX-M-27
gene. All other ESBL positive Escherichia coli sequence
types were found once (n = 1, 6.3 %) and included ST10,
ST69, ST88, ST93, ST349, ST635, ST685, ST2178 and a
new sequence type (ST5929). Three of the 16 ESBL posi-
tive isolates were determined as Klebsiella pneumonia
(18.8 %) consisting of ST22, ST45 and ST48. Additionally,
all three ESBL positive Klebsiella pneumonia isolates har-
bored the blaCTX-M-15 gene. The other three ESBL positive
isolates were determined as Enterobacter cloacae (18.8 %)
of which ST50 was found twice and a new sequence type
(ST421) once. Two of the three ESBL positive Enterobac-
ter cloacae isolates harbored the blaCTX-M-9 gene. In
addition, Table 4 also shows phenotypic resistance
patterns and identified acquired resistance genes to-
wards Q&A, revealing that the presence of acquired
resistance genes in an isolate and phenotypic resist-
ance do not always co-occur.
Table 2 Demographic characteristics of patients
Patient characteristics Totala Hospital 1 Hospital 2 Hospital 3a
Number of unique patients 427 (100) 126 (29.5) 167 (39.1) 134 (31.4)
Sex
Male 217 (51.1) 57 (45.2) 90 (53.9) 70 (53.0)
Used antibiotics 6 months before currentadmission 99 (23.3) 41 (32.5) 34 (20.4) 24 (18.2)
Used antibiotics during current admission 167 (39.3) 33 (26.2) 76 (45.5) 58 (43.9)
Admitted before current admission (up to 1 year) 204 (48.0) 65 (51.6) 77 (46.1) 62 (47.0)
Known HR-GNR positive in the pastb 12 (2.8) 2 (1.6) 7 (4.2) 3 (2.3)
Mean age in years (SD) 65.1 (21.1) 61.2 (22.9) 65.7 (22.4) 68.1 (16.9)
Median time from admission to sampling in days (Range) 3.0 (0–48) 2 (0–29) 4 (0–48) 4 (0–43)
Data are presented as numbers (%) unless indicated otherwise
Percentages were calculated in reference to the specific hospital
aFrom two patients no demographic characteristics were known (in total: 425 patients with known characteristics and 132 for hospital 3)
bKnown HR-GNR positive in the past (since January 2008)
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Table 3 Prevalence rates of rectal HR-GNRs colonization on a patient level
Regional Hospital 1 Hospital 2 Hospital 3
Prevalence 95 % CI Prevalence 95 % CI Prevalence 95 % CI Prevalence 95 % CI
HR-GNR 5.2 % (22/427) 3.6 %–7.9 % 2.4 % (3/126) 0.8 %–6.7 % 7.2 % (12/167) 4.6 %–12.8 % 5.2 % (7/134) 2.6 %–10.4 %
ESBL 3.5 % (15/427) 2.1 %–5.7 % 1.6 % (2/126) 0.4 %–5.6 % 5.4 % (9/167) 2.8 %–9.9 % 3.0 % (4/134) 1.2 %–7.4 %
Q&A 1.6 % (7/427) 0.8 %–3.3 % 0.8 % (1/126) 0.1 %–4.3 % 2.4 % (4/167) 0.9 %–6.0 % 1.5 % (2/134) 0.4 %–5.3 %
Othera 0.2 % (1/427) 0.0 %–1.3 % 0.0 % (0/126) 0.0 %–0.0 % 0.0 % (0/167) 0.0 %–0.0 % 0.7 % (1/134) 0.1 %–3.4 %
aAll other HR-GNR beside ESBL and Q&A, see Table 1
Table 4 Molecular characteristics of HR-GNR positive isolates
Patient Hospital Species MLST HR-GNR
typea, b, c








P1 1 E. coli ST685 ESBL CTX-M-1 - - S S
P2 1 K. pneumoniae ST48 ESBL CTX-M-15, SHV-11 strA, strB oqxA, oqxB, QnrB66 S S
P3 1 E. coli ST69 Q&A - strA, strB, aph(3’)-Ia,
aadA5, aac(3)-IId
- R R
P4 2 E. coli ST5929g ESBL CTX-M-1 - - S S
P5 2 E. coli ST69 ESBL CTX-M-1 aadA5 - S S
P6 2 E. coli ST2178 ESBL CTX-M-3 - - S S
E. coli ND ESBL ND ND ND S S





P7 2 E. coli ST349 ESBL CTX-M-14b strA, strB - S S
P8 2 E. coli ST93 ESBL CTX-M-14b - - S R
P9 2 E. coli ST131 ESBL CTX-M-27 strA, strB, aadA5 - S R
P10 2 E. cloacae ST50 ESBL CTX-M-1 aadA2, aadB oqxA, oqxB, QnrA1 I R
P11 2 E. cloacae ST421g ESBL CTX-M-9 aadB oqxA, oqxB, QnrA1 S S
P12 2 E. cloacae ST50 ESBL CTX-M-9 aadA2, aadB oqxA, oqxB, QnrA1 I R
E. coli ST88 Q&A - aph(3’)-Ic - R R
P13 2 E. coli ST69 Q&A - strA, strB, aac(3)-IId - R R
P14 2 E. coli ST131 Q&A - strA, aac(3)-Iid, aadA5 - R R
P15 2 E. coli ST648 Q&A - aac(6’) Ib-cr aac(6’) Ib-cr R R
P16 3 E. coli ST10 ESBL CTX-M-14 strA, strB, aac(3)-IId,
aadA1, aadA4,
aac(6’) Ib-cr
aac(6’) Ib-cr R S





P18 3 E. coli ST131 ESBL CTX-M-27 - - S R






P20 3 E. coli ST57 Q&A - aph(4)-Ia, aac(3)-IVa,
aadA2
- R R
E. coli ND Q&A - ND ND R R
P21 3 E. coli ST131 Q&A - strA, strB, aac(3)-Iid,
aadA5
- R R
P22 3 S. maltophilia ST152g CTX-R - aph(3’)-IIc, aacA4,
aac(6’) Ib-cr
aac(6’) Ib-cr ND ND
a: ESBL: Extended Spectrum Beta Lactamase; b: Q&A: combined resistance towards Fluoroquinolones and Aminoglycosides; c: CTX-R: resistance towards Co-
trimoxazole; d: QUI: Fluoroquinolones; e: AMG: Aminoglycosides; f: resistance based on VITEK2 results; S sensitive, I intermediate, R resistant, ND not determined,
NA not available, g new sequence type
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Molecular characterization of non-ESBL HR-GNR positive
isolates
Eight (33.3 %) of the 24 genotyped HR-GNR positive
isolates (belonging to eight patients) were non-ESBL
isolates. Seven of these eight isolates showed com-
bined resistance towards Q&A. All seven isolates re-
sistant towards Q&A were determined as Escherichia
coli of which ST69 and ST131 were both found twice
(28.6 %). All other sequence types (ST57, ST88, and
ST648) were recovered once (14.3 %). Only one iso-
late resistant towards Q&A (ST648) harbored the
acquired aac(6’) Ib-cr gene encoding for resistance
towards both Fluoroquinolones and Aminoglycosides.
The other isolates resistant towards Q&A harbored only
acquired resistance genes encoding for Aminoglycoside
resistance although they also showed phenotypic resist-
ance towards Fluoroquinolones. These acquired Amino-
glycoside resistance genes were strA (n = 4, 57.1 %), strB
(n = 3, 42.9 %), aac(3) -IId (n = 3, 42.9 %), aadA5 (n = 3,
42.9 %), aph(3’) -Ia (n = 1, 14.3 %), aph(4) -Ia (n = 1,
14.3 %), aac(3) -IVa (n = 1, 14.3 %), aadA2 (n = 1, 14.3 %)
and aph(3’)-Ic (n = 1, 14.3 %).
One of the eight non-ESBL HR-GNR positive isolates
was determined as Stenotrophomonas maltophilia, which
showed resistance towards co-trimoxazole (12.5 %) and
was characterized as ST152 (new sequence type). This
isolate harbored the acquired sul1 gene encoding for
Sulphonamide resistance.
Associated risk factors for being HR-GNR positive in
hospitalized patients
Table 5 shows the associations between independent var-
iables and the dependent variable (HR-GNR positive in
the prevalence measurement). Both continuous variables
(age and time from admission to sampling) were re-
ported as quartiles (in reference to the first category)
since they were not linearly associated with the outcome.
Being known HR-GNR positive in the past was the only
significant associated risk factor, odds ratio (95 % CI):
7.32 (1.82–29.35), p-value = 0.005. The other tested risk
factors were associated with an increased risk of HR-
GNR positivity, although not significant. The association
with being HR-GNR positive in the past did not mark-
edly change after adjustment for possible confounders
(antibiotic use (during the current and up to 6 months
before the current admission) age, sex, admission before
the current admission and time from start admission to
sampling) using multivariate logistic regression analysis,
odds ratio (95 % CI): 6.54 (1.35–31.61), p-value = 0.020
(Table 6). No significant effect modifiers were identified.
Discussion
The present study shows the results of a cross-sectional
HR-GNR (including ESBL) prevalence measurement in
hospitalized patients of three hospitals in the Dutch re-
gion Kennemerland (with 650,000 inhabitants). In total,
427 rectal swabs derived from unique patients in these
Table 5 Univariate associations between possible risk factors in clinical patients and being HR-GNR positive
Risk factor HR-GNR positive patients (n = 21)a HR-GNR negative patients (n = 404)a Odds ratio (95 % CI) P-value
Sex
Female 9 (42.9) 199 (49.3) 1 (ref) -
Male 12 (57.1) 205 (50.7) 1.29 (0.53–3.14) 0.568
Used antibiotics 6 months before
current admission
6 (28.6) 93 (23.0) 1.34 (0.51–3.55) 0.559
Used antibiotics during admission 10 (47.6) 157 (38.9) 1.43 (0.59–3.45) 0.425
Admitted before current admission
(up to 1 year)
14 (66.7) 190 (47.0) 2.25 (0.89–5.70) 0.086
Known HR-GNR positive in the past 3 (14.3) 9 (2.2) 7.32 (1.82–29.35) 0.005
Age (years)
Group 1 (0–56 years) 4 (19.0) 103 (25.5) 1 (ref) -
Group 2 (57–70 years) 5 (23.8) 99 (24.5) 1.30 (0.34–4.98) 0.701
Group 3 (71–79 years) 9 (42.9) 101 (25.0) 2.30 (0.69–7.69) 0.178
Group 4 (80–94 years) 3 (14.3) 101 (25.0) 0.77 (0.17–3.50) 0.730
Time from admission to sampling (days)
Group 1 (0–1 days) 7 (33.3) 126 (31.2) 1 (ref) -
Group 2 (2–3 days) 3 (14.3) 90 (22.3) 0.60 (0.15–2.38) 0.468
Group 3 (4–6 days) 3 (14.3) 85 (21.0) 0.64 (0.16–2.53) 0.519
Group 4 (7–48 days) 8 (38.1) 103 (25.5) 1.40 (0.49–3.98) 0.531
aIn total, data for 425 patients were available for analyses, as for two patients demographic data were unknown
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hospitals were analyzed and resulted in a total HR-GNR
and ESBL prevalence rate of 5.2 and 3.5 %, respectively.
Furthermore, 7 patients (1.6 %) were positive with an
isolate resistant towards Q&A, and from one patient
(0.2 %) a Stenotrophomonas maltophilia resistant to-
wards co-trimoxazole was isolated. In line with other
Dutch prevalence studies, no CPE positive bacteria were
found, indicating a relatively low prevalence in our region.
Several Dutch studies have previously reported about
the ESBL prevalence rates among different human pop-
ulations. First, Overdevest et al. found a rectal ESBL
colonization prevalence of 4.9 % within hospitalized pa-
tients [7]. Second, a prevalence survey among 125 resi-
dents living in five nursing homes and two (hospital)
rehabilitation wards in the central region of the
Netherlands showed an ESBL prevalence of 6.0 % [8].
Third, a study among 720 patients with gastrointestinal
complaints visiting the general practitioner showed an
ESBL prevalence of 10.1 % [9]. Fourth, two studies re-
ported on the ESBL prevalence among travelers (before
travel) resulting in an ESBL prevalence rate of 8.6 and
9.0 % [22, 23]. Fifth, a cross-sectional ESBL prevalence
measurement performed in a representative sample of
the Dutch community population showed an ESBL
prevalence of 4.7 % [24]. A comparison between the
ESBL prevalence rate in our present study (3.5 %) and
the other studies showed that the ESBL prevalence rate
in our region was relatively low. A possible explanation
for this difference could be the different culture
methods that were used. Some studies used an (selective
or non-selective) enrichment broth, which is associated
with higher sensitivities compared with direct culture
methods [25, 26]. Furthermore, differences in population
characteristics or a geographical variation in risk factors
may also explain the differences in ESBL prevalence rates.
All phenotypic characterized ESBL positive isolates in
our study harbored ESBL genes, mostly blaCTX-M
(88.2 %). WGS showed that the blaCTX-M-1 (25.0 %),
blaCTX-M-15 (18.8 %), blaCTX-M-14b and blaCTX-M-9 (both
12.5 %) ESBL genes were found most often. In line with
our results, another study among hospitalized patients
isolated the blaCTX-M-1 (45.8 %) ESBL gene most often,
followed by blaCTX-M-15 (16.7 %) and blaTEM-52 (12.5 %)
[7]. Surprisingly, a study among a representative sample
of the Dutch community population also isolated the
ESBL gene blaCTX-M-1 (35 %), blaCTX-M-15 (33 %) and
blaCTX-M-14 (18 %) most often, showing that isolates ob-
tained from hospitalized and non-hospitalized individ-
uals share similar ESBL genes [24]. This finding suggests
that the positive HR-GNR patients may have already
been positive at admission and act as a reservoir for
other patients. In addition, studies among cats, dogs and
chicken (retail) meat isolated the blaCTX-M-1 most fre-
quently, indicating that shared reservoirs and/or trans-
mission dynamics exist [11, 12]. Some studies showed
other distributions in ESBL genes. A study among symp-
tomatic general practitioner patients with gastrointes-
tinal complaints, found predominantly blaCTX-M-15
(47 %) ESBL-genes [9]. Furthermore, the two studies
that investigated the ESBL prevalence among healthy
Table 6 Multivariate logistic regression model between possible risk factors in clinical patients
Unadjusted association Fully adjusted modela
Risk factor Odds ratio (95 % CI) P-value Odds ratio (95 % CI) P-value
Sex 1.29 (0.53–3.14) 0.568 1.12 (0.43–2.91) 0.823
Used antibiotics 6 months before current admission 1.34 (0.51–3.55) 0.559 0.84 (0.28–2.51) 0.756
Used antibiotics during admission 1.43 (0.59–3.45) 0.425 1.15 (0.41–3.23) 0.791
Admitted before current admission (up to 1 year) 2.25 (0.89–5.70) 0.086 2.21 (0.80–6.10) 0.126
Known HR-GNR positive in the past 7.32 (1.82–29.35) 0.005 6.54 (1.35–31.61) 0.020
Age (years)
Group 1 (0–56 years) 1 (ref) - 1 (ref) -
Group 2 (57–70 years) 1.30 (0.34–4.98) 0.701 0.84 (0.20–3.45) 0.806
Group 3 (71–79 years) 2.30 (0.69–7.69) 0.178 1.73 (0.49–6.15) 0.395
Group 4 (80–94 years) 0.77 (0.17–3.50) 0.730 0.60 (0.12–2.93) 0.530
Time from admission to sampling (days)
Group 1 (0–1 days) 1 (ref) - 1 (ref) -
Group 2 (2–3 days) 0.60 (0.15–2.38) 0.468 0.47 (0.11–2.01) 0.311
Group 3 (4–6 days) 0.64 (0.16–2.53) 0.519 0.52 (0.12–2.29) 0.385
Group 4 (7–48 days) 1.40 (0.49–3.98) 0.531 1.10 (0.34–3.62) 0.870
aCorrected for (1) Antibiotic use during current admission, (2) Antibiotic use up 6 months before current admission, (3) sex, (4) age, (5) admitted before current
admission, (6) time from start admission to sampling and (7) known HR-GNR positive in the past
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travelers (before travel) found predominantly blaCTX-M-15
(47 %) and blaCTX-M-9 (90 %) ESBL genes [22, 23]. These
differences may be explained by heterogeneity in study
populations. Travelers, symptomatic general practitioner
patients and hospitalized patients possibly show different
risk behavior, which may be reflected in the molecular typ-
ing results. More research is needed to further elucidate
these population differences. As shown, most Dutch ESBL
prevalence studies report predominantly blaCTX-M ESBL
genes and a great variation in Escherichia coli sequence
types that is in line with our results.
As shown in our study, 6 out of 7 phenotypically
characterized isolates resistant towards Q&A had no
acquired resistance genes encoding for quinolone re-
sistance, suggesting that quinolone resistance in these
isolates was mainly caused by chromosomal muta-
tions. The same was seen for ESBL positive isolates
that showed phenotypical resistance towards fluoro-
quinolones or aminoglycosides (not both). As described
earlier by Guan et al., plasmid-encoded quinolone re-
sistance genes do not confer quinolone resistance by
themselves, but augment the effect of other resistance
mutations [27]. Probably the same conclusion is applic-
able to acquired Aminoglycoside resistance genes and
phenotypic expression. More research is needed to elu-
cidate the role of these resistance genes and phenotypic
expression.
Traveling (predominantly to South Asia) and having
a high degree of contact with broilers are today’s
most important identified risk factors for colonization
with ESBL positive bacteria [12, 22, 23, 28, 29]. In
our study, we analyzed several potential risk factors
for HR-GNR colonization. Antibiotic use (during and/
or 6 months before admission) did show a higher
odds ratio for HR-GNR positivity (including ESBL),
although this association was not significant. The same
was found for sex (higher odds for males), ‘admission be-
fore the current admission (up to one year)’ and age (for
the first three quartiles). Being known HR-GNR positive
in the past was the only significantly associated risk factor,
also when corrected for possible confounders. Addition-
ally, studies carried out among long term rehabilitation
patients also identified ‘being known HR-GNR positive’ as
independent risk factor for HR-GNR colonization [30, 31].
This finding suggests that colonization with HR-GNRs
persists for a longer period and should not be ignored at
re-admission at the hospital. Additional longitudinal stud-
ies are needed to quantify the influence of the period of
HR-GNR colonization since this information is essential
to assess the importance of isolating patients at readmis-
sion [6]. Another studied risk factor, time to sampling
(from start admission to sampling) was not significantly
associated with HR-GNR colonization, indicating that the
role of nosocomial colonization was minimal. This finding
suggests that basic hygiene in the studied hospitals is
good. Even when we excluded the first quartile (0–1 day),
as one may hypothesize that HR-GNR positive patients in
this group were already positive at admission, no signifi-
cant association was detected. To elucidate the influence
of this possible risk factor, prospective study designs are
needed in which all patients are screened at admission
and during hospitalization (at specific time intervals).
Furthermore, we suggest that future studies aiming at
identifying transmissions routes and/or reservoirs for
HR-GNR involving pigs, horses or other (companion)
animals, should include both humans and animals (and
their isolates) that are epidemiologically linked. When
such studies are performed in a longitudinal design,
transmission dynamics as well as origin and transmis-
sion of resistance genes can be studied (from humans to
animals or the other way around).
To our knowledge, no studies are available that deter-
mined the colonization prevalence of Q&A resistant
Enterobacteriaceae. We recommend for future studies to
incorporate all defined HR-GNRs, in addition to ESBLs,
in prevalence studies, in order to obtain a more compre-
hensive overview of colonization with HR-GNRs.
The present study has several limitations. First, only a
small number of potential risk factors were included in
the risk factor analysis lacking the ability to identify
more ‘potential’ risk factors such as contact with HR-
GNR positive household members, travel history, food
preferences, other medication use, having pets and stay
or transfer from a nursing home. Second, as mentioned
before, no enrichment broth was used which could have
underestimated the HR-GNR prevalence rate. Third, his-
toric data on antibiotic use were retrospectively retrieved
from the hospital pharmacy database, which only contains
data on clinical prescribed antibiotics, and not on anti-
biotic use in the primary care setting. Fourth, our study
was performed in a single region of the Netherlands with
a relatively small number of cases limiting the power to
identify all important risk factors. Therefore, our results
should be interpreted with caution.
Conclusion
In conclusion, no local differences in HR-GNR preva-
lence rates and micro-organisms were found between
the three regional hospitals. In addition, the Dutch
region Kennemerland showed similar ESBL prevalence
rates among the hospitalized patients population in
comparison to other Dutch regions. When previously
HR-GNR positive patients are readmitted they should be
screened for HR-GNR colonization since colonization
with GR-GNRs could be prolonged. Molecular typing
results showed that comparable ESBL genotypes were
found as earlier described in both humans and ani-
mals supporting the hypothesis of multiple reservoirs
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and risk factors. Future studies must focus more on
these postulated reservoirs and risk factors with ap-
propriate study designs.
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